Comparative Study of Rebamipide & Betamethasone in Managing Stomatopyrosis in Oral Submucous Fibrosis (OSMF) Patients
Abstract
Background: Oral submucous fibrosis (OSF) is commonly seen in the Indian subcontinent affecting individuals of all age groups. It is a potentially malignant disorder caused almost exclusively by the use of smokeless forms of tobacco products. The malignant transformation rates vary from 3 to 19%. The standard of care (SOC) in managing OSF includes habit cessation, intralesional steroid and hyaluronidase injections, and mouth opening exercises.
Objectives: To evaluate the efficacy of rebamipide to reduce the oral burning sensation associated with OSMF as compared to coventional Betamethasone intralesional injection.
Materials and Methods: After providing information about the study and obtaining consent, these individuals were divided into two groups of 15 each using random sampling method. Patients in the rebamipide group (group I) were prescribed 100 mg tablets of rebamipide thrice a day for 21 days. The other 15 patients (group II) were given SOC, intralesional betamethasone injection 4 mg/mL once a week for 4 weeks. Visual analog scale (VAS) with 11 points (0–10) was used to assess burning sensation in the first visit, and change in the burning sensation was assessed after every 7th day on VAS in both the groups.
Results: The improvement in the VAS score in each visit was significant (p < 0.05) in the 1st, 2nd, 3rd, and 4th visit. The VAS score between the 4th and 5th visit failed to reach a statistically significant level (p>0.05). The VAS score was significantly different between the rebamipide and betamethasone group (p > 0.05) in the third & fourth visits.
Conclusion: Our results showed that rebamipide was equally efficacious if not better than the betamethasone intralesional injections.
References
Joanna Baptist et al Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis, The Journal of Contemporary Dental Practice, December 2016; 17(12):1009-1012. doi: https://doi.org/10.5005/jp-journals-10024-1972
Sarode SC, Sarode GS. Better grade of tumor differentiation of oral squamous cell carcinoma arising in background of oral submucous fibrosis. Med Hypotheses 2013 Oct; 81(4): 540-543. Doi: https://doi.org/10.1016/j.mehy.2013.07.001
Chen HM, Hsieh RP, Yang H, Kuo YS, Kuo MY, Chiang CP. HLA typing in Taiwanese patients with oral sub mucous fibrosis. J Oral Pathol Med 2004 Apr; 33(4):191-199. doi: https://doi.org/10.1111/j.0904-2512.2004.00195.x
Jeng JH, Wang YJ, Chang WH, Wu HL, Li CH, Uang BJ, Kang JJ, Lee JJ, Hahn LJ, Lin BR, et al. Reactive oxygen species are crucial for hydroxychavicol toxicity toward KB epithelial cells. Cell Mol Life Sci 2004 Jan; 61(1):83-96 doi: https://doi.org/10.1007/s00018-003-3272-8
World Health Organization. Regional office for South-East Asia global adult tobacco survey (GATS): India country report. New Delhi: WHO-SEARO; 2009 [cited 2014 Mar 25]. Available from: http://www.searo.who.int/LinkFiles/Regional_ Tobacco_ Surveillance_ System_GATS_India.pdf
Gupta S, Reddy MV, Harinath BC. Role of oxidative stress and antioxidants in aetiopathogenesis and management of oral submucous fibrosis. Indian J Clin Biochem 2004 Jan; 19(1):138-141. Doi: https://dx.doi.org/10.1007%2FBF02872409
Kim H, Seo JY, Kim KH. Inhibition of lipid peroxidation, NF-kB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 2000 Mar; 45(3):621-628. Doi: https://doi.org/10.1023/a:1005474013988
Lai DR, Chen HR, Lin LM, Huang YL, Tsai CC. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases. J Oral Pathol Med 1995 Oct; 24(9):402-406. Doi: https://doi.org/10.1111/j.1600-0714.1995.tb01209.x
Rajendra R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res 2006 Oct-Dec; 17(4):190-198. Doi: https://doi.org/10.4103/0970-9290.29865
Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 Feb; 103(2):207-213. Doi: https://doi.org/10.1016/j.tripleo.2006.07.011
Lin HJ, Lin JC. Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. Oral Dis 2007 Aug; 13(4):407-413 doi: https://doi.org/10.1111/j.1601-0825.2006.01313.x
Kakar PK, Puri RK, Venkatachalam VP. Oral submucous fibrosis--treatment with hyalase. J Laryngol Otol 1985 Jan; 99(1): 57-59. doi: https://doi.org/10.1017/s0022215100096286
Shimoyama T, Fukuda S, Liu Q, Fukuda Y, Nakaji S, Sugawara K. Characteristics of attenuating effects of rebamipide, an anti-ulcer agent, on oxidative bursts of human neutrophils. J Pharmacol Sci 2003 Feb; 91(2):153-157.
lijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, Shimosegawa T. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 2009 Jul; 54(7):1500-1507. doi: https://doi.org/10.1007/s10620-008-0507-4
Naito Y, Kuroda M, Mizushima K, Takagi T, Handa O, Kokura S, Yoshida N, Ichikawa H, Yoshikawa T. Transcriptome analysis for cytoprotective actions of rebamipide against indomethacin-nduced gastric mucosal injury in rats. J Clin Biochem Nutr 2007 Nov; 41(3):202-210. doi: http://dx.doi.org/10.3164/jcbn.2007029
Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drug R D 2003; 4(1):19-28. doi: https://doi.org/10.2165/00126839-200304010-00002
